Technological advances empower the modification of NK cells and renewed potential for therapeutic uses in cancer and ...

Researchers in South Korea have proposed a novel cancer immunotherapy approach that could complement existing CAR-T (Chimeric ...

3 Zhejiang Clinical Research Center of Hepatobiliary and Pancreatic Diseases, Hangzhou, China 4 The Innovation Center for the Study of Pancreatic Diseases of Zhejiang Province, Hangzhou, China ...

For this purpose, we fused the PE38 toxin with the specific C5 sdAb antibody, previously developed by our group for canine B-cell lymphoma. This resulted in a stable and highly specific C5-PE38 ...

Following a successful Type B end-of-phase 2 meeting, the FDA has approved the start of a phase 3 trial of linperlisib in peripheral T-cell lymphoma. The FDA has granted clearance to initiate a global ...

In a strong validation of the company’s clinical trial, Imugene Ltd’s Phase 1b trial for its azer-cel off-the-shelf, allogeneic, CD19 CAR T therapy in relapsed/refractory diffuse large B-cell lymphoma ...

Non-Hodgkin's lymphoma (NHL) occurs when lymphocytes called ... the appearance of the lymph nodes and cells, and the number of cells in the blood. The cancer will be assigned a stage grouping between ...

The condition occurs when the body doesn’t have enough healthy red blood cells (RBCs) to carry oxygen efficiently, leading to fatigue, weakness, and other health complications. Iron deficiency ...

The AuToDeCRA-2 study seeks to prove it is possible to train white blood cell commanders - dubbed the "generals" of the immune system - to order other "soldier" cells to stop attacking healthy ...